Enlivex Therapeutics (NASDAQ:ENLV) Receives “Buy” Rating from D. Boral Capital

Enlivex Therapeutics (NASDAQ:ENLV)‘s stock had its “buy” rating restated by analysts at D. Boral Capital in a research report issued to clients and investors on Tuesday,Benzinga reports. They currently have a $13.00 price objective on the stock.

Enlivex Therapeutics Price Performance

ENLV opened at $1.54 on Tuesday. Enlivex Therapeutics has a fifty-two week low of $0.81 and a fifty-two week high of $1.76. The firm has a market capitalization of $36.42 million, a PE ratio of -2.33 and a beta of 0.79. The company’s 50-day moving average is $1.11 and its 200 day moving average is $1.07.

Enlivex Therapeutics (NASDAQ:ENLV) last posted its earnings results on Friday, May 30th. The company reported ($0.15) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.01. As a group, analysts expect that Enlivex Therapeutics will post -0.7 EPS for the current year.

Institutional Investors Weigh In On Enlivex Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Jane Street Group LLC increased its stake in Enlivex Therapeutics by 527.4% in the 1st quarter. Jane Street Group LLC now owns 80,759 shares of the company’s stock valued at $78,000 after buying an additional 67,886 shares during the last quarter. Millennium Management LLC purchased a new stake in Enlivex Therapeutics in the 4th quarter valued at about $742,000. Two Sigma Securities LLC purchased a new stake in Enlivex Therapeutics in the 4th quarter valued at about $26,000. Finally, Renaissance Technologies LLC grew its position in shares of Enlivex Therapeutics by 112.6% during the 4th quarter. Renaissance Technologies LLC now owns 158,992 shares of the company’s stock valued at $186,000 after acquiring an additional 84,203 shares during the period. Hedge funds and other institutional investors own 1.02% of the company’s stock.

About Enlivex Therapeutics

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.